| Trial ID: | L3532 |
| Source ID: | NCT05184868
|
| Associated Drug: |
At247
|
| Title: |
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 1
|
| Interventions: |
DRUG: AT247|DRUG: NovoLog|DRUG: Fiasp
|
| Outcome Measures: |
Primary: Area under Curve for serum insulin, 0-30 minutes|Area under Curve for Glucose Infusion Rate, 0-60 minutes |
|
| Sponsor/Collaborators: |
Sponsor: Arecor Limited
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2022-01-03
|
| Completion Date: |
2022-09-09
|
| Results First Posted: |
|
| Last Update Posted: |
2022-09-13
|
| Locations: |
ProSciento, Inc, Chula Vista, California, 91911, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT05184868
|
